Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037305 · ClinicalTrials.gov registry record · NA
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey
A NA study of Pharmacogenomic Testing, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 2
- Study locations
NCT05037305 is a NA study of Pharmacogenomic Testing that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT05037305, a NA study of Pharmacogenomic Testing, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after pregnancy. The unique physiology of childhood and pregnancy demand validation of pharmacogenetic signals prior to clinical implementation. These knowledge gaps are compounded for individuals from minority populations, who have been underrepresented and thus underserved by genomic research and specifically pharmacogenetic studies. The primary objective of this project is to advance research and support clinical implementation in pharmacogenetics for children and pregnant women. This work will illuminate knowledge of, attitudes about, and priorities for pharmacogenetics, and will assess the impact of a brief educational video on knowledge and attitudes around pharmacogenetic testing. The investigators will assess the knowledge and attitudes regarding pharmacogenetic testing among diverse cohorts of children with chronic conditions and pregnant women, before and after receiving pharmacogenetic test results. Participants will be randomized to view an educational video about pharmacogenetic testing either at the time of receiving their pharmacogenetic test results, or at a later time. The investigators will perform surveys before and after pharmacogenomic testing and return of results, and before and after watching the educational video.
Conditions Studied
Interventions
- OTHER Educational video
Study Locations (2)
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05037305
The ClinicalTrials.gov registry entry for NCT05037305 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacogenomic Testing appearing as the primary indexed condition, and to 1 intervention - of which Educational video is the first listed.
NCT05037305 reports 2 study locations spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05037305 about?
NCT05037305 is a clinical study titled "VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey". The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after p...
What is the current status of trial NCT05037305?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-06-30. Estimated completion is 2026-04-30.
What conditions does trial NCT05037305 study?
This clinical trial studies the following conditions: Pharmacogenomic Testing.
What interventions are being tested in trial NCT05037305?
The interventions under investigation include: Educational video (OTHER).
Who is sponsoring clinical trial NCT05037305?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037305 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenomic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.